Global Virus Like Particles

Virus Like Particles Comprehensive Study by Type (Adeno-Associated Virus, HIV, Hepatitis B Virus, Hepatitis C Virus, Others), Application (Vaccines, Mycoviruses, Virus Research, Therapeutic and Imaging Agents, Others) Players and Region - Global Market Outlook to 2026

Virus Like Particles Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Virus Like Particles Market?

Virus like particles are molecules that mimic viruses but are not infectious. It is used to create vaccines against diseases such as human papillomavirus (HPV), malaria, hepatitis B, and more. VLP vaccines are being used more often due to their increased safety and ability to trigger strong immune responses, and their ability to be made on a large scale and their potential for being used in inhaled vaccinations over injected vaccinations is an attractive advantage of the vaccine.

The market study is being classified by Type (Adeno-Associated Virus, HIV, Hepatitis B Virus, Hepatitis C Virus and Others), by Application (Vaccines, Mycoviruses, Virus Research, Therapeutic and Imaging Agents and Others) and major geographies with country level break-up.

GlaxoSmithKline (United Kingdom), Merck & Co., Inc (United States), Novavax (United States), Takeda (Japan), Medicago Inc. (Canada), MedImmune, LLC (United States), TechnoVax (United States), Agilvax (United States), Allergy Therapeutics (United Kingdom), Serum Institute of India (India) and GeoVax Labs (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cytos Biotechnology (Switzerland) and Xiamen Innovax Biotech (China).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Virus Like Particles market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Virus Like Particles market by Type, Application and Region.

On the basis of geography, the market of Virus Like Particles has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence of Infectious Diseases
  • Improving Healthcare Infrastructure in Developing Countries

Market Trend
  • Expansion of Customized Vaccines

Restraints
  • Side Effects of Virus-Like Particles Vaccination include Pain, Swelling, or etc.

Opportunities
  • Rising Investments towards the Research and Development for More Effective Vaccines
  • Growth in Emerging Market

Challenges
  • High Cost Associated with the Development of a Vaccine


Market Leaders and some development strategies
In Nov 2020, Medicago and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant. The Coronavirus-Like Particle COVID-19 vaccine candidate (CoVLP) is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).
In Sept 2020, Allergy Therapeutics plc announces further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field. Allergy Therapeutics (the Group) entered into an exclusive license agreement with Saiba AG and DeepVax GmbH to use their patented VLP technology platform to develop and commercialize vaccines targeting solid cancer tumors, atopic dermatitis, asthma, and psoriasis.


Key Target Audience
Virus-Like Particles Manufacturer, Virus Like Particles Suppliers/Distributors, Raw Material Suppliers, Pharmaceutical Industry, Potential Investors and Research and Development Firm

Report Objectives / Segmentation Covered

By Type
  • Adeno-Associated Virus
  • HIV
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Others
By Application
  • Vaccines
  • Mycoviruses
  • Virus Research
  • Therapeutic and Imaging Agents
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Infectious Diseases
      • 3.2.2. Improving Healthcare Infrastructure in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with the Development of a Vaccine
    • 3.4. Market Trends
      • 3.4.1. Expansion of Customized Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Virus Like Particles, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Virus Like Particles (Value)
      • 5.2.1. Global Virus Like Particles by: Type (Value)
        • 5.2.1.1. Adeno-Associated Virus
        • 5.2.1.2. HIV
        • 5.2.1.3. Hepatitis B Virus
        • 5.2.1.4. Hepatitis C Virus
        • 5.2.1.5. Others
      • 5.2.2. Global Virus Like Particles by: Application (Value)
        • 5.2.2.1. Vaccines
        • 5.2.2.2. Mycoviruses
        • 5.2.2.3. Virus Research
        • 5.2.2.4. Therapeutic and Imaging Agents
        • 5.2.2.5. Others
      • 5.2.3. Global Virus Like Particles Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Virus Like Particles: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novavax (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medicago Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MedImmune, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. TechnoVax (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Agilvax (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Allergy Therapeutics (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Serum Institute of India (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GeoVax Labs (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Virus Like Particles Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Virus Like Particles (Value)
      • 7.2.1. Global Virus Like Particles by: Type (Value)
        • 7.2.1.1. Adeno-Associated Virus
        • 7.2.1.2. HIV
        • 7.2.1.3. Hepatitis B Virus
        • 7.2.1.4. Hepatitis C Virus
        • 7.2.1.5. Others
      • 7.2.2. Global Virus Like Particles by: Application (Value)
        • 7.2.2.1. Vaccines
        • 7.2.2.2. Mycoviruses
        • 7.2.2.3. Virus Research
        • 7.2.2.4. Therapeutic and Imaging Agents
        • 7.2.2.5. Others
      • 7.2.3. Global Virus Like Particles Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Virus Like Particles: by Type(USD Million)
  • Table 2. Virus Like Particles Adeno-Associated Virus , by Region USD Million (2015-2020)
  • Table 3. Virus Like Particles HIV , by Region USD Million (2015-2020)
  • Table 4. Virus Like Particles Hepatitis B Virus , by Region USD Million (2015-2020)
  • Table 5. Virus Like Particles Hepatitis C Virus , by Region USD Million (2015-2020)
  • Table 6. Virus Like Particles Others , by Region USD Million (2015-2020)
  • Table 7. Virus Like Particles: by Application(USD Million)
  • Table 8. Virus Like Particles Vaccines , by Region USD Million (2015-2020)
  • Table 9. Virus Like Particles Mycoviruses , by Region USD Million (2015-2020)
  • Table 10. Virus Like Particles Virus Research , by Region USD Million (2015-2020)
  • Table 11. Virus Like Particles Therapeutic and Imaging Agents , by Region USD Million (2015-2020)
  • Table 12. Virus Like Particles Others , by Region USD Million (2015-2020)
  • Table 13. South America Virus Like Particles, by Country USD Million (2015-2020)
  • Table 14. South America Virus Like Particles, by Type USD Million (2015-2020)
  • Table 15. South America Virus Like Particles, by Application USD Million (2015-2020)
  • Table 16. Brazil Virus Like Particles, by Type USD Million (2015-2020)
  • Table 17. Brazil Virus Like Particles, by Application USD Million (2015-2020)
  • Table 18. Argentina Virus Like Particles, by Type USD Million (2015-2020)
  • Table 19. Argentina Virus Like Particles, by Application USD Million (2015-2020)
  • Table 20. Rest of South America Virus Like Particles, by Type USD Million (2015-2020)
  • Table 21. Rest of South America Virus Like Particles, by Application USD Million (2015-2020)
  • Table 22. Asia Pacific Virus Like Particles, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Virus Like Particles, by Type USD Million (2015-2020)
  • Table 24. Asia Pacific Virus Like Particles, by Application USD Million (2015-2020)
  • Table 25. China Virus Like Particles, by Type USD Million (2015-2020)
  • Table 26. China Virus Like Particles, by Application USD Million (2015-2020)
  • Table 27. Japan Virus Like Particles, by Type USD Million (2015-2020)
  • Table 28. Japan Virus Like Particles, by Application USD Million (2015-2020)
  • Table 29. India Virus Like Particles, by Type USD Million (2015-2020)
  • Table 30. India Virus Like Particles, by Application USD Million (2015-2020)
  • Table 31. South Korea Virus Like Particles, by Type USD Million (2015-2020)
  • Table 32. South Korea Virus Like Particles, by Application USD Million (2015-2020)
  • Table 33. Taiwan Virus Like Particles, by Type USD Million (2015-2020)
  • Table 34. Taiwan Virus Like Particles, by Application USD Million (2015-2020)
  • Table 35. Australia Virus Like Particles, by Type USD Million (2015-2020)
  • Table 36. Australia Virus Like Particles, by Application USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Virus Like Particles, by Type USD Million (2015-2020)
  • Table 38. Rest of Asia-Pacific Virus Like Particles, by Application USD Million (2015-2020)
  • Table 39. Europe Virus Like Particles, by Country USD Million (2015-2020)
  • Table 40. Europe Virus Like Particles, by Type USD Million (2015-2020)
  • Table 41. Europe Virus Like Particles, by Application USD Million (2015-2020)
  • Table 42. Germany Virus Like Particles, by Type USD Million (2015-2020)
  • Table 43. Germany Virus Like Particles, by Application USD Million (2015-2020)
  • Table 44. France Virus Like Particles, by Type USD Million (2015-2020)
  • Table 45. France Virus Like Particles, by Application USD Million (2015-2020)
  • Table 46. Italy Virus Like Particles, by Type USD Million (2015-2020)
  • Table 47. Italy Virus Like Particles, by Application USD Million (2015-2020)
  • Table 48. United Kingdom Virus Like Particles, by Type USD Million (2015-2020)
  • Table 49. United Kingdom Virus Like Particles, by Application USD Million (2015-2020)
  • Table 50. Netherlands Virus Like Particles, by Type USD Million (2015-2020)
  • Table 51. Netherlands Virus Like Particles, by Application USD Million (2015-2020)
  • Table 52. Rest of Europe Virus Like Particles, by Type USD Million (2015-2020)
  • Table 53. Rest of Europe Virus Like Particles, by Application USD Million (2015-2020)
  • Table 54. MEA Virus Like Particles, by Country USD Million (2015-2020)
  • Table 55. MEA Virus Like Particles, by Type USD Million (2015-2020)
  • Table 56. MEA Virus Like Particles, by Application USD Million (2015-2020)
  • Table 57. Middle East Virus Like Particles, by Type USD Million (2015-2020)
  • Table 58. Middle East Virus Like Particles, by Application USD Million (2015-2020)
  • Table 59. Africa Virus Like Particles, by Type USD Million (2015-2020)
  • Table 60. Africa Virus Like Particles, by Application USD Million (2015-2020)
  • Table 61. North America Virus Like Particles, by Country USD Million (2015-2020)
  • Table 62. North America Virus Like Particles, by Type USD Million (2015-2020)
  • Table 63. North America Virus Like Particles, by Application USD Million (2015-2020)
  • Table 64. United States Virus Like Particles, by Type USD Million (2015-2020)
  • Table 65. United States Virus Like Particles, by Application USD Million (2015-2020)
  • Table 66. Canada Virus Like Particles, by Type USD Million (2015-2020)
  • Table 67. Canada Virus Like Particles, by Application USD Million (2015-2020)
  • Table 68. Mexico Virus Like Particles, by Type USD Million (2015-2020)
  • Table 69. Mexico Virus Like Particles, by Application USD Million (2015-2020)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Virus Like Particles: by Type(USD Million)
  • Table 82. Virus Like Particles Adeno-Associated Virus , by Region USD Million (2021-2026)
  • Table 83. Virus Like Particles HIV , by Region USD Million (2021-2026)
  • Table 84. Virus Like Particles Hepatitis B Virus , by Region USD Million (2021-2026)
  • Table 85. Virus Like Particles Hepatitis C Virus , by Region USD Million (2021-2026)
  • Table 86. Virus Like Particles Others , by Region USD Million (2021-2026)
  • Table 87. Virus Like Particles: by Application(USD Million)
  • Table 88. Virus Like Particles Vaccines , by Region USD Million (2021-2026)
  • Table 89. Virus Like Particles Mycoviruses , by Region USD Million (2021-2026)
  • Table 90. Virus Like Particles Virus Research , by Region USD Million (2021-2026)
  • Table 91. Virus Like Particles Therapeutic and Imaging Agents , by Region USD Million (2021-2026)
  • Table 92. Virus Like Particles Others , by Region USD Million (2021-2026)
  • Table 93. South America Virus Like Particles, by Country USD Million (2021-2026)
  • Table 94. South America Virus Like Particles, by Type USD Million (2021-2026)
  • Table 95. South America Virus Like Particles, by Application USD Million (2021-2026)
  • Table 96. Brazil Virus Like Particles, by Type USD Million (2021-2026)
  • Table 97. Brazil Virus Like Particles, by Application USD Million (2021-2026)
  • Table 98. Argentina Virus Like Particles, by Type USD Million (2021-2026)
  • Table 99. Argentina Virus Like Particles, by Application USD Million (2021-2026)
  • Table 100. Rest of South America Virus Like Particles, by Type USD Million (2021-2026)
  • Table 101. Rest of South America Virus Like Particles, by Application USD Million (2021-2026)
  • Table 102. Asia Pacific Virus Like Particles, by Country USD Million (2021-2026)
  • Table 103. Asia Pacific Virus Like Particles, by Type USD Million (2021-2026)
  • Table 104. Asia Pacific Virus Like Particles, by Application USD Million (2021-2026)
  • Table 105. China Virus Like Particles, by Type USD Million (2021-2026)
  • Table 106. China Virus Like Particles, by Application USD Million (2021-2026)
  • Table 107. Japan Virus Like Particles, by Type USD Million (2021-2026)
  • Table 108. Japan Virus Like Particles, by Application USD Million (2021-2026)
  • Table 109. India Virus Like Particles, by Type USD Million (2021-2026)
  • Table 110. India Virus Like Particles, by Application USD Million (2021-2026)
  • Table 111. South Korea Virus Like Particles, by Type USD Million (2021-2026)
  • Table 112. South Korea Virus Like Particles, by Application USD Million (2021-2026)
  • Table 113. Taiwan Virus Like Particles, by Type USD Million (2021-2026)
  • Table 114. Taiwan Virus Like Particles, by Application USD Million (2021-2026)
  • Table 115. Australia Virus Like Particles, by Type USD Million (2021-2026)
  • Table 116. Australia Virus Like Particles, by Application USD Million (2021-2026)
  • Table 117. Rest of Asia-Pacific Virus Like Particles, by Type USD Million (2021-2026)
  • Table 118. Rest of Asia-Pacific Virus Like Particles, by Application USD Million (2021-2026)
  • Table 119. Europe Virus Like Particles, by Country USD Million (2021-2026)
  • Table 120. Europe Virus Like Particles, by Type USD Million (2021-2026)
  • Table 121. Europe Virus Like Particles, by Application USD Million (2021-2026)
  • Table 122. Germany Virus Like Particles, by Type USD Million (2021-2026)
  • Table 123. Germany Virus Like Particles, by Application USD Million (2021-2026)
  • Table 124. France Virus Like Particles, by Type USD Million (2021-2026)
  • Table 125. France Virus Like Particles, by Application USD Million (2021-2026)
  • Table 126. Italy Virus Like Particles, by Type USD Million (2021-2026)
  • Table 127. Italy Virus Like Particles, by Application USD Million (2021-2026)
  • Table 128. United Kingdom Virus Like Particles, by Type USD Million (2021-2026)
  • Table 129. United Kingdom Virus Like Particles, by Application USD Million (2021-2026)
  • Table 130. Netherlands Virus Like Particles, by Type USD Million (2021-2026)
  • Table 131. Netherlands Virus Like Particles, by Application USD Million (2021-2026)
  • Table 132. Rest of Europe Virus Like Particles, by Type USD Million (2021-2026)
  • Table 133. Rest of Europe Virus Like Particles, by Application USD Million (2021-2026)
  • Table 134. MEA Virus Like Particles, by Country USD Million (2021-2026)
  • Table 135. MEA Virus Like Particles, by Type USD Million (2021-2026)
  • Table 136. MEA Virus Like Particles, by Application USD Million (2021-2026)
  • Table 137. Middle East Virus Like Particles, by Type USD Million (2021-2026)
  • Table 138. Middle East Virus Like Particles, by Application USD Million (2021-2026)
  • Table 139. Africa Virus Like Particles, by Type USD Million (2021-2026)
  • Table 140. Africa Virus Like Particles, by Application USD Million (2021-2026)
  • Table 141. North America Virus Like Particles, by Country USD Million (2021-2026)
  • Table 142. North America Virus Like Particles, by Type USD Million (2021-2026)
  • Table 143. North America Virus Like Particles, by Application USD Million (2021-2026)
  • Table 144. United States Virus Like Particles, by Type USD Million (2021-2026)
  • Table 145. United States Virus Like Particles, by Application USD Million (2021-2026)
  • Table 146. Canada Virus Like Particles, by Type USD Million (2021-2026)
  • Table 147. Canada Virus Like Particles, by Application USD Million (2021-2026)
  • Table 148. Mexico Virus Like Particles, by Type USD Million (2021-2026)
  • Table 149. Mexico Virus Like Particles, by Application USD Million (2021-2026)
  • Table 150. Research Programs/Design for This Report
  • Table 151. Key Data Information from Secondary Sources
  • Table 152. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Virus Like Particles: by Type USD Million (2015-2020)
  • Figure 5. Global Virus Like Particles: by Application USD Million (2015-2020)
  • Figure 6. South America Virus Like Particles Share (%), by Country
  • Figure 7. Asia Pacific Virus Like Particles Share (%), by Country
  • Figure 8. Europe Virus Like Particles Share (%), by Country
  • Figure 9. MEA Virus Like Particles Share (%), by Country
  • Figure 10. North America Virus Like Particles Share (%), by Country
  • Figure 11. Global Virus Like Particles share by Players 2020 (%)
  • Figure 12. Global Virus Like Particles share by Players (Top 3) 2020(%)
  • Figure 13. Global Virus Like Particles share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 17. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck & Co., Inc (United States) Revenue: by Geography 2020
  • Figure 19. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 20. Novavax (United States) Revenue: by Geography 2020
  • Figure 21. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Takeda (Japan) Revenue: by Geography 2020
  • Figure 23. Medicago Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Medicago Inc. (Canada) Revenue: by Geography 2020
  • Figure 25. MedImmune, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 26. MedImmune, LLC (United States) Revenue: by Geography 2020
  • Figure 27. TechnoVax (United States) Revenue, Net Income and Gross profit
  • Figure 28. TechnoVax (United States) Revenue: by Geography 2020
  • Figure 29. Agilvax (United States) Revenue, Net Income and Gross profit
  • Figure 30. Agilvax (United States) Revenue: by Geography 2020
  • Figure 31. Allergy Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. Allergy Therapeutics (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 34. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 35. GeoVax Labs (United States) Revenue, Net Income and Gross profit
  • Figure 36. GeoVax Labs (United States) Revenue: by Geography 2020
  • Figure 37. Global Virus Like Particles: by Type USD Million (2021-2026)
  • Figure 38. Global Virus Like Particles: by Application USD Million (2021-2026)
  • Figure 39. South America Virus Like Particles Share (%), by Country
  • Figure 40. Asia Pacific Virus Like Particles Share (%), by Country
  • Figure 41. Europe Virus Like Particles Share (%), by Country
  • Figure 42. MEA Virus Like Particles Share (%), by Country
  • Figure 43. North America Virus Like Particles Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co., Inc (United States)
  • Novavax (United States)
  • Takeda (Japan)
  • Medicago Inc. (Canada)
  • MedImmune, LLC (United States)
  • TechnoVax (United States)
  • Agilvax (United States)
  • Allergy Therapeutics (United Kingdom)
  • Serum Institute of India (India)
  • GeoVax Labs (United States)
Additional players considered in the study are as follows:
Cytos Biotechnology (Switzerland) , Xiamen Innovax Biotech (China)
Select User Access Type

Key Highlights of Report


Mar 2021 225 Pages 55 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Virus Like Particles Quantitative research analysis
Global Virus Like Particles Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Prevalence of Infectious Diseases " is seen as one of major growth factors of Virus Like Particles Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Virus Like Particles Report?

Have a Query? Click Here

Other Related Reports

Pet Vaccine Comprehensive Study by Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines), Mode of Administra...
$ 3650
Typhoid Vaccine Comprehensive Study by Type (Oral, Injection), Application (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - Global M...
$ 3500
Clostridium Difficile Treatment Comprehensive Study by Type (Narrow Spectrum Antibiotics, Broad Spectrum Antibiotics), Route of Administration (Oral, Intravenous / Parenteral), Distribution Channel (...
$ 3750
Clinical Trial Packaging Comprehensive Study by Packaging (Syringes, Vials & Ampoules, Bottles, Bags & Pouches, Tubes, Sachets, Kits or Packs, Others), End-User (Research Laboratories, Clinical Resea...
$ 3500
Omeprazole Comprehensive Study by Type (Capsule, Powder, Tablet, Suspension), Application (Gastroesophageal Reflux Disease (GERD), Barrett's Oesophagus, Duodenal Ulcer, Erosive Esophagitis, Hiatal He...
$ 3750
Primary Biliary Cirrhosis Drug Comprehensive Study by Type (Budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, Others), Application (Clinic, Hospital, Others), Tests (Computed Tomography (CT), Ultr...
$ 3450